NEJM Retracts Pivotal Data for Amgen's Autoimmune Drug Tavneos Amid FDA Investigation

Pivotal data supporting Amgen's autoimmune drug Tavneos have been retracted from The New England Journal of Medicine (NEJM) following an ongoing FDA investigation. The retraction was requested by two academic authors who cited concerns that results for nine patients were re-evaluated after the trial was unblinded, which NEJM editor-in-chief Eric Rubin stated was inconsistent with proper research conduct. This development adds to existing challenges for Tavneos, which was approved in 2021 for ANCA-associated vasculitis, as the FDA has previously raised concerns about its data and cases of drug-induced liver injury, and the European Medicines Agency (EMA) recently proposed revoking its marketing authorization due to 'incorrect and misleading' clinical data.

Context

Tavneos, approved in 2021 for treating ANCA-associated vasculitis, has faced scrutiny over its clinical data. The recent retraction from NEJM follows concerns from academic authors about the re-evaluation of patient results after the trial was unblinded. The FDA has previously expressed concerns regarding the drug's data and instances of liver injury, while the EMA has suggested revoking its marketing authorization.

Why it matters

The retraction of pivotal data for Tavneos raises significant concerns about the integrity of clinical research. This situation could impact the drug's credibility and its acceptance in the medical community. The ongoing FDA investigation may lead to further scrutiny of the drug's safety and efficacy, affecting patient treatment options.

Implications

This retraction and the FDA investigation could lead to decreased confidence in Tavneos among physicians and patients. If the FDA or EMA takes further action, it may restrict the drug's use or availability, impacting patients who rely on it for treatment. The situation could also prompt broader discussions about regulatory oversight and the reliability of clinical trial data.

What to watch

The FDA's ongoing investigation will be critical to follow, as it may result in additional findings regarding Tavneos. Stakeholder responses, including those from healthcare providers and patients, will also be important to monitor. Future announcements from the EMA regarding Tavneos' marketing status could further influence its availability in Europe.